Strategic analysis for market access, pricing, HTA and regulatory leaders navigating how medicines actually reach patients — across global markets.
Live Last read · last published · next check
Seven of 22 innovative medicines were not submitted for Swiss reimbursement over U.S. MFN concerns. The deeper issue: what happens when a national price stops being national.
The method that binds twenty-seven countries is written by whoever staffs the room.
It was never meant to be collected. It was meant to be signed away.
Coverage policy didn’t change. Access did. That distinction is the entire business.
Six variables. One grid. And the launch call nobody wants to put in writing.
The medicine didn't change. The price barely did. What moved was the line that defines value.
The same patent that made Enbrel unaffordable is why Colorado can't touch the price.
The molecule was never the bottleneck — the payer is. And no AI is pointed at the gate where patients actually wait.
A 60% tax rate on operating income. A 523-day wait for new medicines — the longest in Western Europe. And 64% of companies that now expect Washington’s pricing policy to cut their French launches...
Price reviews every year since 2021 that only ever move in one direction. Now Tokyo needs drug prices to rise to survive Washington's MFN — and discovers it never built the lever.
The EMA approved it. The EU’s first Joint Clinical Assessment could not say whether it beats the option already in use...
Eight PICOs. Three populations. Seven questions answered with nothing — and the eighth resting on an effective sample of six to fourteen patients...
AstraZeneca wants the United States to be half its revenue by 2030. When a chief executive threatens to walk away from Europe, the skill is reading which half of the sentence is the negotiation.
Regulators decide whether a medicine can be sold. Payers decide whether it can be funded. Systems decide whether it is ever used.
Because payers do not read your value story in the order pharma writes it. They ask four questions — and every weak answer changes the price.
€195 per month. One million eligible patients. Nineteen countries reference French prices. The first domino in European obesity access just fell.
The first JCA endorsed. A new antihypertensive class in 20 years. Ozempic negotiated at $274. TrumpRx hits 600 generics. And 66 days to the tariff wall.
Royal Decree 415/2026 gives Spain its first national HTA framework — and a hard deadline for the assessment. But the clock runs on the one part of the process that was never the bottleneck.
[video] AI is already inside the evidence chain. Discovery, trials, endpoints, manufacturing, submissions. Most regulatory teams have not caught up.
The Reuters audit, the 46brooklyn data, the Insmed pause. Eight months of MFN has produced one clear finding — and Europe still has no answer.
